Flynn James E

Flynn James E is listed in filings as Director, other* Director by Deputization, 10% Owner at Larimar Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 20, 2026, including purchase activity and sale activity. Recent filings connect the profile to Larimar Therapeutics, Inc. (LRMR), Nuvalent, Inc. (NUVL), ARS Pharmaceuticals, Inc. (SPRY), and BiomX Inc. (PHGE). The current snapshot covers public activity from Jul 11, 2024 to May 20, 2026. Reported amounts are shown as $183.7K to $5.4M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.